Labcorp (LH) – Research Analysts’ Weekly Ratings Changes

Labcorp (NYSE: LH) recently received a number of ratings updates from brokerages and research firms:

• 10/29/2026 – Labcorp had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $355.00 price target on the stock.
• 10/29/2026 – Labcorp had its price target raised by UBS Group from $380.00 to $420.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Labcorp had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $388.00 price target on the stock.
• 10/29/2026 – Labcorp had its price target raised by Truist Financial from $365.00 to $395.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Labcorp had its price target raised by Robert W. Baird from $361.00 to $396.00. They now have an “outperform” rating on the stock.
• 10/28/2026 – Labcorp had its price target raised by Barclays from $330.00 to $380.00. They now have an “equal weight” rating on the stock.
• 10/28/2026 – Labcorp was given a new $410.00 price target by Leerink Partners.
• 10/21/2026 – Labcorp was upgraded by Weiss Ratings from “buy (b+)” to “buy (a-)”.
• 10/6/2026 – Labcorp was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 9/21/2026 – Labcorp had its price target raised by Truist Financial from $350.00 to $365.00. They now have a “buy” rating on the stock.
• 9/11/2026 – Labcorp had its price target raised by UBS Group from $361.00 to $380.00. They now have a “buy” rating on the stock.
• 9/11/2026 – Labcorp had its price target raised by Barclays from $320.00 to $330.00. They now have an “equal weight” rating on the stock.

Labcorp Stock Performance

Shares of LH opened at $353.39 on Wednesday. The company has a quick ratio of 1.22, a current ratio of 1.41 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 52-week low of $244.52 and a 52-week high of $371.00. The stock has a 50 day moving average price of $323.91 and a 200 day moving average price of $288.58. The company has a market capitalization of $28.70 billion, a price-to-earnings ratio of 28.99, a price-to-earnings-growth ratio of 2.01 and a beta of 0.86.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share for the quarter, topping the consensus estimate of $4.64 by $0.14. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.18 EPS. Research analysts predict that Labcorp Holdings Inc. will post 18.51 EPS for the current fiscal year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s payout ratio is presently 23.63%.

Insider Activity at Labcorp

In related news, Director Kerrii Anderson sold 3,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total value of $954,060.00. Following the completion of the sale, the director directly owned 6,563 shares of the company’s stock, valued at $2,087,165.26. This represents a 31.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richelle Parham sold 1,078 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $361.22, for a total value of $389,395.16. Following the transaction, the director owned 2,288 shares in the company, valued at $826,471.36. This represents a 32.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,747 shares of company stock valued at $2,839,263 in the last three months. 0.84% of the stock is currently owned by company insiders.

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.